The changing natural history of spinal muscular atrophy type 1
Citation Manager Formats
Make Comment
See Comments
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
Abstract
Background: Noninvasive ventilation has become increasingly available to spinal muscular atrophy (SMA) patients since the early 1990s. This is expected to have improved survival for SMA type 1 patients.
Objective: To assess whether there has been a change in survival in patients with SMA type 1 between 1980 and 2006.
Methods: We used deidentified, family-reported data from participants in the International Spinal Muscular Atrophy Patient Registry and obtained additional clinical information through a mail-in questionnaire. One hundred forty-three patients with SMA type 1 were included in the analysis. Survival of patients born in 1995–2006 (n = 78) was compared with that of patients born in 1980–1994 (n = 65), using the Kaplan–Meier method and Cox proportional hazards models with age at death as the outcome.
Results: Patients born in 1995 though 2006 had significantly increased survival compared with those born in 1980–1994 (log-rank test, p < 0.001). In a Cox model, patients born in 1995–2006 had a 70% reduction in the risk of death compared with those born in 1980–1994 (hazard ratio [HR] 0.3, 95% CI 0.2–0.5, p < 0.001) over a mean follow-up of 49.9 months (SD 61.1, median 22.0). However, when controlling for demographic and clinical care variables, year of birth was no longer significantly associated with age at death (HR 1.0, 95% CI 0.6–1.8, p = 0.9), whereas ventilation for more than 16 h/d, use of a mechanical insufflation–exsufflation device, and gastrostomy tube feeding showed a significant effect in reducing the risk of death.
Conclusion: Survival in spinal muscular atrophy type 1 patients has increased in recent years, in relation to the growing trend toward more proactive clinical care.
GLOSSARY: BiPAP = bilevel positive airway pressure; HR = hazard ratio; MI-E = mechanical insufflation–exsufflation; SMA = spinal muscular atrophy; YOB = year of birth.
Footnotes
-
Supported by the Spinal Muscular Atrophy (SMA) Foundation (P.K., M.O., J.O., D.C.D.V.); Families of SMA (International SMA Patient Registry); and NIH CTSA Award 1 UL1 RR024156-01 (P.K.).
Disclosure: The authors report no conflicts of interest.
Received February 26, 2007. Accepted in final form May 25, 2007.
AAN Members
We have changed the login procedure to improve access between AAN.com and the Neurology journals. If you are experiencing issues, please log out of AAN.com and clear history and cookies. (For instructions by browser, please click the instruction pages below). After clearing, choose preferred Journal and select login for AAN Members. You will be redirected to a login page where you can log in with your AAN ID number and password. When you are returned to the Journal, your name should appear at the top right of the page.
AAN Non-Member Subscribers
Purchase access
For assistance, please contact:
AAN Members (800) 879-1960 or (612) 928-6000 (International)
Non-AAN Member subscribers (800) 638-3030 or (301) 223-2300 option 3, select 1 (international)
Sign Up
Information on how to subscribe to Neurology and Neurology: Clinical Practice can be found here
Purchase
Individual access to articles is available through the Add to Cart option on the article page. Access for 1 day (from the computer you are currently using) is US$ 39.00. Pay-per-view content is for the use of the payee only, and content may not be further distributed by print or electronic means. The payee may view, download, and/or print the article for his/her personal, scholarly, research, and educational use. Distributing copies (electronic or otherwise) of the article is not allowed.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Emily Gilmore and Dr. Rachel Beekman
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
Population-based analysis of survival in spinal muscular atrophyCamiel A. Wijngaarde, Marloes Stam, Louise A.M. Otto et al.Neurology, March 26, 2020 -
Articles
Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMAL. R. Simard, M-C Bélanger, S. Morissette et al.Neurology, February 05, 2007 -
Articles
SMN mRNA and protein levels in peripheral bloodBiomarkers for SMA clinical trialsC. J. Sumner, S. J. Kolb, G. G. Harmison et al.Neurology, February 15, 2006 -
Research
A multidisciplinary approach to dosing nusinersen for spinal muscular atrophyCarla D. Zingariello, John Brandsema, Elizabeth Drum et al.Neurology: Clinical Practice, September 05, 2019